8-K: Adicet Bio Reports Positive ADI-001 Data, Extends Cash Runway

Adicet Bio announced positive preliminary Phase 1 data for ADI-001 in autoimmune diseases and extended its cash runway into 2H/2027 following a $74.8 million capital raise.

Summary

• Positive preliminary safety and efficacy data from the Phase 1 clinical trial of ADI-001 in lupus nephritis (LN) and systemic lupus erythematosus (SLE) patients were announced.
• The data highlighted rapid and sustained reductions in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) score and Physicians Global Assessment (PGA), improved renal function (including three complete renal responses), and a favorable safety and tolerability profile as of the August 31, 2025 data cut-off date.
• The company plans to request a meeting with the U.S. Food and Drug Administration (FDA) in 1Q/2026 to inform potentially pivotal ADI-001 trial design, with the study anticipated to commence in 2Q/2026.
• Enrollment is ongoing for patients in the Phase 1 study with LN, SLE, systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), stiff person syndrome (SPS), and anti-neutrophil cytoplasmic autoantibody associated vasculitis (AAV).
• A clinical update from the Phase 1 study of ADI-001 in LN, SLE, and SSc is on track to be shared in 1H/2026.
• Patients with treatment-refractory rheumatoid arthritis (RA) are actively being enrolled in a Phase 1 study of ADI-001 evaluating the potential to reduce the need for conditioning.
• A regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer (mCRPC) is planned for submission in 1Q/2026, with initial clinical data expected in 2H/2026.
• An underwritten registered direct offering was completed, raising $74.8 million in net proceeds, which extended the projected cash runway into 2H/2027.
• Research and Development (R&D) expenses for the three months ended September 30, 2025, were $22.9 million, a decrease from $26.3 million in the same period in 2024.
• General and Administrative (G&A) expenses for the three months ended September 30, 2025, were $5.1 million, a decrease from $6.9 million in the same period in 2024.
• Net loss for the three months ended September 30, 2025, was $26.9 million, or $0.29 per basic and diluted share, compared to a net loss of $30.5 million, or $0.34 per basic and diluted share, in the same period in 2024.
• Cash, cash equivalents, and short-term investments were $103.1 million as of September 30, 2025, compared to $176.3 million as of December 31, 2024.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical data for its lead candidate, ADI-001, in significant autoimmune indications, coupled with a successful capital raise that significantly extends its financial runway. The reduction in net loss and operating expenses also contributes positively.

Positives

• Positive preliminary safety and efficacy data for ADI-001 in LN and SLE, showing rapid and sustained reductions in disease activity and improved renal function, including three complete renal responses.
• ADI-001 demonstrated a favorable safety profile with no Grade 2 or higher Cytokine Release Syndrome (CRS) and no cases of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) observed.
• Successfully raised $74.8 million in net proceeds through an underwritten registered direct offering, extending the cash runway into the second half of 2027.
• Research and Development (R&D) expenses decreased to $22.9 million in Q3 2025 from $26.3 million in Q3 2024.
• General and Administrative (G&A) expenses decreased to $5.1 million in Q3 2025 from $6.9 million in Q3 2024.
• Net loss decreased to $26.9 million in Q3 2025 compared to $30.5 million in Q3 2024.

Negatives

• The company reported a continued net loss of $26.9 million for Q3 2025, which, while an improvement, still represents a significant cash burn typical for a clinical-stage biotechnology company.
• Cash, cash equivalents, and short-term investments decreased from $176.3 million as of December 31, 2024, to $103.1 million as of September 30, 2025, prior to the recent capital raise.

Risks

• The effect of global economic conditions and public health emergencies on Adicet's business and financial results, including disruptions to preclinical and clinical studies, business operations, employee hiring and retention, and ability to raise additional capital.
• Adicet's ability to execute on its strategy, including obtaining the requisite regulatory approvals on the expected timeline, if at all.
• Positive results, including interim results, from a preclinical or clinical study may not necessarily be predictive of the results of future or ongoing studies.
• Clinical studies may fail to demonstrate adequate safety and efficacy of Adicet's product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization.
• Regulatory approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable.
• Adicet's ability to meet production and product release expectations.

Future Outlook

Adicet Bio anticipates requesting an FDA meeting in Q1 2026 to discuss the pivotal trial design for ADI-001, with trial initiation targeted for Q2 2026. Clinical updates for ADI-001 in LN, SLE, and SSc are expected in 1H 2026, and for RA in 2H 2026. A regulatory filing for ADI-212 in mCRPC is planned for Q1 2026, with initial clinical data expected in 2H 2026. The recent capital raise has extended the company's cash runway into the second half of 2027.

Management Comments

• "We were pleased to announce positive preliminary data last month from seven SLE and LN patients treated in our Phase 1 trial of ADI-001, underscoring its broad potential as a transformative, off-the-shelf, one-time therapy for autoimmune diseases." Chen Schor, President and Chief Executive Officer.
• "We are now preparing to discuss the trial design for a potentially pivotal study of ADI-001 with the FDA in the first quarter of 2026, with initiation targeted for the second quarter of 2026." Chen Schor.
• "As part of our broader clinical strategy, we are also exploring the potential to reduce or eliminate the need for conditioning with a separate Phase 1 trial of ADI-001 in treatment-refractory RA patients." Chen Schor.
• "In addition, we are continuing to advance ADI-212... and expect to submit a regulatory filing for the mCRPC program in the first quarter of 2026 and share initial clinical data in the second half of 2026, subject to regulatory clearance." Chen Schor.
• "Supported by our recent capital raise in October, which extended our cash runway into the second half of 2027, we are well-positioned to continue clinical execution across our pipeline of differentiated gamma delta 1 CAR T therapies." Chen Schor.

Industry Context

Adicet Bio operates in the highly competitive and innovative fields of allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The positive preliminary data for ADI-001 in lupus nephritis and systemic lupus erythematosus positions it as a potential leader in off-the-shelf, one-time therapies for autoimmune conditions, a space with significant unmet medical needs and high commercial potential. The development of ADI-212 for metastatic castration-resistant prostate cancer also targets a challenging solid tumor indication, leveraging advanced gene-editing and armoring techniques to enhance potency, which is a key trend in next-generation CAR T therapies. The successful capital raise is crucial for clinical-stage biotechs to fund extensive research and development.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct comparison.
• The safety profile of ADI-001, with no Grade 2 or higher Cytokine Release Syndrome (CRS) and no Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), is generally favorable compared to some autologous CAR T therapies which have historically shown higher rates of these adverse events.
• The development of 'off-the-shelf' allogeneic therapies represents a significant advancement over autologous therapies, aiming for broader accessibility and reduced manufacturing complexity, aligning with a major industry trend towards more scalable cell therapies.

Stakeholder Impact

• Shareholders: Positive impact due to promising clinical data, extended cash runway, and reduced burn rate, potentially increasing investor confidence and future valuation.
• Patients: Potential for a transformative, off-the-shelf, one-time therapy for severe autoimmune diseases and mCRPC, offering new treatment options with a favorable safety profile.
• Employees: Increased job security and stability due to extended cash runway and continued pipeline advancement.
• Regulatory Authorities: Engagement with the FDA for pivotal trial design indicates progress towards potential market approval.

Next Steps

• Request a meeting with the FDA in 1Q/2026 to inform potentially pivotal ADI-001 trial design.
• Initiate potentially pivotal ADI-001 study in LN or LN and SLE patients in 2Q/2026.
• Provide a clinical update from the Phase 1 study of ADI-001 in LN, SLE, and SSc in 1H/2026.
• Continue enrolling patients in the Phase 1 study of ADI-001 for LN, SLE, SSc, IIM, SPS, AAV, and treatment-refractory RA.
• Submit a regulatory filing for ADI-212 in mCRPC in 1Q/2026.
• Share initial clinical data from the ADI-212 program in 2H/2026, subject to regulatory clearance.
• Provide a clinical update on the Phase 1 trial of ADI-001 in treatment-refractory RA in 2H/2026.

Key Dates

Recommendation

The positive preliminary Phase 1 data for ADI-001 in lupus nephritis and systemic lupus erythematosus, demonstrating both strong efficacy (rapid and sustained reductions in disease activity, improved renal function) and a favorable safety profile (no Grade 2+ CRS or ICANS), is a significant de-risking event for a clinical-stage biotech. This data supports the potential for ADI-001 as a transformative, off-the-shelf therapy. Furthermore, the successful capital raise of $74.8 million, extending the cash runway into the second half of 2027, provides crucial financial stability to advance the pipeline without immediate dilution concerns. The reduction in net loss and operating expenses also indicates improved financial management. The planned FDA meeting for a pivotal trial design and the advancement of ADI-212 in mCRPC add further catalysts. These factors collectively suggest a strong positive outlook for the company's prospects and stock performance.

Keywords

Adicet Bio, ACET, gamma delta T cell therapy, autoimmune diseases, cancer, ADI-001, lupus nephritis, SLE, systemic lupus erythematosus, ADI-212, prostate cancer, mCRPC, clinical trial, Phase 1, FDA, financial results, biotechnology, CAR T therapy, cash runway, capital raise